Stock ARCT ARCTURUS THERAPEUTICS HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Market Closed - Nasdaq
Other stock markets
 01:30:00 29/06/2024 am IST 		5-day change 1st Jan Change
24.35 USD -0.41% Intraday chart for Arcturus Therapeutics Holdings Inc. -11.29% -22.77%
20/06 Arcturus Therapeutics Holdings Inc. Appoints Moncef Slaoui, Ph.D., to Board of Directors CI
14/06 Arcturus Therapeutics Holdings Insider Sold Shares Worth $1,601,500, According to a Recent SEC Filing MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble
MT
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
CI
Arcturus Therapeutics Holdings Inc. Announces Positive Development for Cystic Fibrosis Program
CI
Achilles Therapeutics Collaborating With Arcturus Therapeutics to Evaluate mRNA Personalized Cancer Vaccines
MT
Achilles Therapeutics plc Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
CI
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
CI
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q1 Revenue $38M, vs. Street Est of $17.7M
MT
Arcturus Therapeutics Swings to Q4 Net Loss, Revenue Drops
MT
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q4 Revenue $34M, vs. Street Est of $37.9M
MT
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Arcturus Gets European Orphan Medicinal Product Label For ARCT-032 to Treat Cystic Fibrosis
MT
Passport Technologies, Inc. Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA Delivery Systems
CI
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster
CI
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults
CI
Arcturus Therapeutics Says FDA Grants Orphan Drug Designation for ARCT-032 to Treat Cystic Fibrosis
MT
Arcturus Therapeutics Q3 Net Loss Narrows as Revenue Surges; Shares Soar Premarket
MT
Arcturus Therapeutics Q3 Net Loss Narrows as Revenue Surges
MT
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Posts Q3 Revenue $45.1M, vs. Street Est of $15.9M
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARCT Stock
  4. News Arcturus Therapeutics Holdings Inc.
  5. Highlights